Steven Dayan

Steven Dayan

Auto-generated profile, based on publicly available information

Steven Dayan

Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology, University of Illinois at Chicago, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Dermatologic Surgery
Verified
Journal Article
Closed access
SDSteven H. Dayan
Steven H. Dayan
JAJohn P. Arkins
John P. Arkins
APAmit B. Patel
Amit B. Patel
TGThomas J. Gal
Thomas J. Gal

1 May 2008 in Aesthetic Surgery Journal
Verified
Journal Article
Open access
SDS Dayan
S Dayan
BBB Bassichis
B Bassichis
Over the last decade, there has been a shift in the way aesthetic surgeons approach facial rejuvenation. With recognition of the value of volume enhancement in achieving a more youthful appearance, as well as the ease of office procedures offering minimal downtime and predictable results, there has been a concomitant explosion in the soft tissue filler market. Given the vast array of filler products currently available, the decision of which facial filler to use in specific situations can be complicated and confusing. A physician's selection of facial filler(s) should be based on a solid understanding of the various filler products, appropriate patient selection, and the physician's proficiency in injection techniques. We present a review of the most widely used fillers, offering guidance on patient selection and effective injection techniques.

15 September 2018 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
SDSteven Dayan
Steven Dayan
ARAlexander Rivkin
Alexander Rivkin
JSJonathan M Sykes
Jonathan M Sykes
CTCraig F Teller
Craig F Teller
SWSusan H Weinkle
Susan H Weinkle
CGConor J Gallagher
Conor J Gallagher
Background: The impact of facial aesthetic treatments not only enhances physical appearance but also psychological well-being. Accordingly, patient-reported outcomes are increasingly utilized as an important measure of treatment success. Observer-reported outcomes are a relevant yet often overlooked measure of treatment benefit. Objectives: The authors aimed to evaluate the impact of panfacial aesthetic treatment on the perception of an individual in a variety of social contexts. Methods: A total 2000 men and women (aged 18-65 years) participated in an online study designed to capture the blinded observer’s social perception of pretreatment and posttreatment patients who received panfacial aesthetic treatment in the HARMONY study. Perceptions relevant to character traits, age, attractiveness, and social status were evaluated. Observers were divided into 2 groups. Single image respondents (n = 1500) viewed 6 single, randomized patient images (3 pretreatment, 3 posttreatment), and paired image respondents (n = 500) viewed 6 pretreatment and posttreatment image pairs. Results: Single image respondents reported significantly (P < 0.05) higher levels of agreement that posttreatment subjects appeared to possess more positive character traits (eg, healthy and approachable), were more socially adept, younger, more attractive, more successful at attracting others, and possessed a higher social status. Paired image respondents also reported a higher level of agreement for posttreatment images being aligned with positive character traits, representative of a younger and more attractive individual, and one with a higher social status. Conclusions: The results suggest that the positive impact of minimally invasive panfacial treatment extends beyond enhancing physical appearance and highlights the importance of social perception and observer-reported outcomes in aesthetic medicine.

18 January 2011 in Facial Plastic Surgery
Verified
Journal Article
Closed access
SDSteven H Dayan
Steven H Dayan
JAJohn P Arkins
John P Arkins
RBRenata Brindise
Renata Brindise
The purpose of this study was to review the clinical course of reported hypersensitivity reactions associated with use of soft tissue fillers and the response of these reactions to treatment. In this comprehensive literature review, we identified ~40 published reports that together reported numerous adverse reactions associated with use of nonpermanent soft tissue fillers; however, very few of these reactions were consistent with type I immediate or type IV delayed hypersensitivity reactions. Based on their clinical course and response to treatment, most reported hypersensitivity reactions are likely due to an infectious process. Although there are no confirmed reports of biofilm reactions associated with nonpermanent fillers, the possibility of bacterial contaminants should be considered in acute or chronic inflammatory reactions associated with use of nonpermanent soft tissue fillers. Early treatment with antibiotics is recommended.

1 February 2018 in Aesthetic Surgery Journal
Verified
Journal Article
Open access
PDF file
SDSteven H Dayan
Steven H Dayan
JSJoel Schlessinger
Joel Schlessinger
KBKenneth Beer
Kenneth Beer
LDLisa M Donofrio
Lisa M Donofrio
DJDerek H Jones
Derek H Jones
CSChristine Somogyi
Christine Somogyi
ATX-101 (deoxycholic acid injection) is the only injectable drug approved for submental fat (SMF) reduction. In the phase 3 REFINE trials, adults with moderate or severe SMF who were dissatisfied with the appearance of their face/chin were eligible to receive up to 6 treatment sessions with ATX-101 (2 mg/cm2) or placebo. Primary and secondary endpoints, evaluated at 12 weeks after last treatment, significantly favored ATX-101 supporting its efficacy for reducing SMF and the psychological impact of SMF, and increasing satisfaction with the appearance of the face/chin. To evaluate the efficacy and safety of ATX-101 by treatment session. This post hoc analysis used pooled data from the REFINE trials to evaluate efficacy endpoints and adverse events following each treatment session to further characterize the ATX-101 treatment response and safety profile. In both treatment groups, mean injection volume declined over subsequent treatment sessions, though more markedly in the ATX-101 group. The majority of ATX-101–treated patients achieved a ≥1-grade improvement in SMF within 2 to 4 treatment sessions based on either clinician or patient assessment. Furthermore, 19.1% of ATX-101–treated patients (vs 3.9% of placebo-treated patients) received fewer than 6 treatment sessions owing to patient satisfaction with treatment or lack of sufficient SMF for further treatment. In both treatment groups, the incidence/severity of common injection-site adverse events declined over subsequent treatment sessions. Although up to 6 treatment sessions were permitted in the REFINE trials, most ATX-101–treated patients achieved an improvement in SMF within 2 to 4 treatment sessions. Level of Evidence: 3

1 November 2013 in Facial Plastic Surgery Clinics of North America
Verified
Journal Article
Closed access
SDSteven H. Dayan
Steven H. Dayan